argenx (ARGX) Q4 2025 earnings review
Hypergrowth Meets Operating Leverage
argenx delivered a flawless execution quarter, transitioning from a cash-burning biotech into a highly profitable commercial powerhouse. Full-year 2025 product net sales surged 90% to $4.15B, driven by the relentless expansion of the VYVGART franchise in gMG and CIDP. More importantly, operating profitability is accelerating: the company generated $1.05B in operating profit for the year, reversing a $21.7M loss in 2024. While bottom-line Net Income appears to have decelerated year-over-year in Q4, this is purely an optical illusion caused by a one-time $725M tax benefit recognized in Q4 2024. The underlying business is firing on all cylinders, combining massive top-line expansion with profound operating leverage.
🐂 Bull Case
Q4 product net sales hit $1.28B (+74% YoY). Reaching 19,000 patients globally proves the pre-filled syringe (PFS) and CIDP launch are successfully expanding the market rather than just cannibalizing IV sales.
The business has reached critical mass. FY25 operating margin jumped to 25% as revenue growth (90%) drastically outpaced the growth in operating expenses (40%).
🐻 Bear Case
Combined R&D and SG&A expenses hit $2.73B in FY25, missing the company's prior $2.5B guidance. If top-line growth decelerates, this bloated fixed cost base could squeeze margins.
Phase 2a data for adimanebart (MuSK agonist) failed to support continued development in ALS, putting more pressure on empasiprubart to carry the next-generation pipeline.
⚖️ Verdict: 🟢🟢
Very Bullish. argenx is executing a masterclass in commercial biotech scaling. The combination of 90% revenue growth, a swing to >$1B in operating profit, and a deep pipeline of label expansions makes this one of the highest-quality growth stories in the sector.
Key Themes
Operating Leverage is Accelerating
The most important takeaway from this print is the sheer scale of operating leverage. Total operating income in Q4 grew 74% to $1.32B, while total operating expenses grew 45% to $954M. This resulted in Q4 operating profit skyrocketing 256% YoY from $103M to $367.6M. The company has officially cleared the heavy-investment commercialization phase and is now printing cash.
VYVGART Label Expansion Pipeline
The addressable market for VYVGART continues to widen. The Phase 3 ADAPT OCULUS study met its primary endpoint for ocular myasthenia gravis (oMG), paving the way for an sBLA submission. Concurrently, the PDUFA date for seronegative gMG is set for May 10, 2026. These expansions pull treatment into earlier lines of therapy, cementing efgartigimod's dominance before competitors can gain a foothold.
Next-Gen Delivery Modalities: The Autoinjector
argenx is fortifying its moat through formulation technology. While the pre-filled syringe (PFS) utilizing Halozyme's ENHANZE technology drove 2025 growth, management expects the VYVGART SC autoinjector to launch in 2027. This continuous innovation in self-administration reduces patient friction, expands the prescriber base, and builds a formidable barrier against incoming FcRn competitors.
Optical Net Income Reversing Due to Base Effects
Net income decelerated sharply in Q4, dropping from $774M in 24Q4 to $533M in 25Q4. However, this is an optical illusion. Q4 2024 included a massive, one-time $725M deferred tax benefit. Excluding this tax distortion, pre-tax profit actually accelerated dramatically from $86.5M in 24Q4 to $403.2M in 25Q4. Investors must focus on Operating Profit to gauge actual performance.
Macro Impact: Medicare Part D Redesign Weighs on Gross-to-Net
While not explicitly quantified in the Q4 release, earlier quarters indicated that gross-to-net (G2N) deductions increased from ~12% to ~20% due to the PFS launch and the broader macro impact of the Medicare Part D redesign (IRA). While massive volume growth has entirely masked this margin headwind so far, it structurally lowers the net revenue realization per unit and requires monitoring.
Adimanebart Fails in ALS
The pipeline is not invincible. Management disclosed that Phase 2a data for adimanebart (MuSK agonist) in Amyotrophic Lateral Sclerosis (ALS) does not support continued development. While the CMS registrational study remains on track for Q3 2026, the ALS failure removes a massive potential upside catalyst from the mid-term narrative.
Missed Operating Expense Guidance
Management previously guided for combined 2025 R&D and SG&A expenses of 'approximately $2.5 billion.' The actual result came in at $2.73B ($1.36B R&D + $1.37B SG&A). The revenue outperformance makes this forgivable, but an overspend of nearly $230M demonstrates the immense capital required to simultaneously support a global commercial rollout and a 10-molecule clinical pipeline.
Other KPIs
The balance sheet is a fortress. Cash, cash equivalents, and current financial assets swelled to $4.44B at the end of FY25, up from $3.38B at the end of FY24. Operating cash flow before interest and taxes generated $941M for the year, confirming the business is now fully self-funding its massive R&D ambitions.
Stable. Cost of sales was $149.7M on $1,285.7M of product revenue, translating to an impressive 88.4% gross margin. This consistency indicates that manufacturing efficiencies are successfully offsetting the higher royalty burdens associated with the Halozyme ENHANZE delivery technology.
Guidance
This target action date represents a major near-term catalyst. Expanding the label to include anti-AChR antibody-negative patients (MuSK+, LRP4+, and triple seronegative) will unlock a vital new patient pool and reinforce VYVGART's position as the foundational therapy for all gMG patients.
Topline results for the anti-C2 candidate in Multifocal Motor Neuropathy (MMN) are expected late 2026. This is the critical proof-point for argenx's ability to build a second multi-billion-dollar franchise outside of the FcRn mechanism.
Key Questions
Capital Allocation Strategy
With operating cash flow now positive and $4.44B in liquid assets, how is management prioritizing capital deployment? Are share buybacks or aggressive M&A on the table, or will this strictly fund internal pipeline expansion?
Autoinjector Transition Dynamics
With the VYVGART SC autoinjector slated for 2027, how do you foresee the transition dynamics from the current PFS? What are the expected impacts on gross-to-net and patient adherence?
SG&A Run-Rate
You exceeded the $2.5B combined OpEx guidance for 2025 by a significant margin. As we model 2026, should we expect SG&A to scale linearly with revenue, or is there a plateau approaching for the commercial infrastructure?